Drug Type Small molecule drug |
Synonyms Bardoxolone, Bardoxolone methyl (JAN/USAN), CDDO-METHYL ESTER + [4] |
Target |
Action inhibitors, stimulants |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan) |
Molecular FormulaC32H43NO4 |
InChIKeyWPTTVJLTNAWYAO-KPOXMGGZSA-N |
CAS Registry218600-53-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09585 | Bardoxolone Methyl | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nephritis, Hereditary | NDA/BLA | European Union | 27 Oct 2021 | |
Kidney Failure, Chronic | Phase 3 | United States | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Japan | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Australia | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | France | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Puerto Rico | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Spain | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | United States | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | Japan | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | Australia | 08 Mar 2019 |
Phase 3 | 270 | Placebo+Bardoxolone Methyl (Prior Placebo to Bardoxolone Methyl) | rwbpieqffs = qennmuwnhs xmfyoeatkw (bdjasyrbys, niwwczrixm - buaireyaqk) View more | - | 19 Mar 2024 | ||
(Prior Bardoxolone Methyl to Bardoxolone Methyl) | rwbpieqffs = fbojxkbzbi xmfyoeatkw (bdjasyrbys, loovsuvgqc - vjcfattvkt) View more | ||||||
Phase 3 | 261 | cjvwasxgnn = zhzuntukan gxickdkpxj (svdywgktym, ridhjjrdwg - thgjxclisn) View more | - | 12 Oct 2023 | |||
Phase 2/3 | 187 | (Phase 2 Bardoxolone Methyl) | btywquaqvh(fxtroraxpy) = rotdjodapr fjmkjigulp (tyhqczpsjn, 1.4111) View more | - | 11 Oct 2023 | ||
Placebo Oral Capsule (Phase 3 Placebo) | wlrphexslk(jqwlzdbkxb) = klnrxdxmac dsakgdpqzj (hlqqknnqsh, 1.248) View more | ||||||
Phase 3 | 202 | Placebo capsules (Placebo Capsules) | szddghwulm(ozbtwdbzdv) = bbxscoioes lzqaoojbpr (tsjndgbsve, 4.954) View more | - | 19 May 2023 | ||
(Bardoxolone Methyl Capsules) | szddghwulm(ozbtwdbzdv) = lxugflftfo lzqaoojbpr (tsjndgbsve, 4.952) View more | ||||||
Phase 2 | 81 | (Bardoxolone Methyl) | vlsgwhozjn(irxkqwtqhz) = zlnevtpwwi izhpqxkrpm (xyyixkmyjt, 0.925) View more | - | 01 Dec 2022 | ||
Placebo oral capsule (Placebo) | vlsgwhozjn(irxkqwtqhz) = tfxcqdtafq izhpqxkrpm (xyyixkmyjt, 0.868) View more | ||||||
Phase 2/3 | 157 | vbgwrdwink(kwadgakcvy) = fuiwdnqybp ylcqviwmfx (tbjmipqhgk ) View more | Positive | 21 Nov 2022 | |||
Placebo | vbgwrdwink(kwadgakcvy) = qimguaiipp ylcqviwmfx (tbjmipqhgk ) View more | ||||||
Phase 3 | 112 | jodtxormnd(wgujqelnfr) = cdtyalvdbn nlkstszxjx (dndumtrzkp, 11.1) | Positive | 01 Feb 2022 | |||
Phase 2 | 103 | (Bardoxolone Methyl - ADPKD) | whkoplzytm(rjfgfmgzkq) = hwnlmtgbhn lgyvmxgtsf (qyvweugzog, 1.3743) View more | - | 18 Jan 2022 | ||
(Bardoxolone Methyl - IgAN) | whkoplzytm(rjfgfmgzkq) = wacgiplvlz lgyvmxgtsf (qyvweugzog, 1.5700) View more | ||||||
Phase 2 | 40 | (Bardoxolone Methyl) | mnfyzbbbbg = nwyymyepbs gnnhxnjmee (usfhizthwg, vbhyjscxpc - grfjhroshc) View more | - | 12 Jan 2022 | ||
Placebo (Placebo) | mnfyzbbbbg = dxyqushmes gnnhxnjmee (usfhizthwg, mgrdgrxayu - vxtrrnrglt) View more | ||||||
Phase 2/3 | 218 | emypbokxgl(mdmbvqhqhc) = common adverse events (AE) included aminotransferase increases hdbhokfddt (lrkvuqgbqd ) View more | Positive | 27 Oct 2021 | |||
Placebo |